ArticleJournal of gastrointestinal oncology2026

Beyond trastuzumab: redefining first-line HER2-positive gastroesophageal cancer with bispecific HER2 targeting.

Rishi Bothara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.